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Summary
Congressional interest in facilitating U.S. technological innovation led to the
passage of P.L. 96-517, Amendments to the Patent and Trademark Act (commonly
referred to as the Bayh-Dole Act after its two main sponsors).  The act grants patent
rights to inventions arising out of government- sponsored research and development
(R&D) to certain types of entities with the expressed purpose of encouraging the
commercialization of new technologies through cooperative ventures between and
among the research community, small business, and industry. 
Patents provide an economic incentive for companies to pursue further
development and commercialization.  Studies have shown that research funding
accounts for approximately one-quarter of the costs associated with bringing a new
product to market.  Patent ownership is seen as a way to encourage the additional,
and often substantial investment necessary for generating new goods and services.
In an academic setting, the possession of title to inventions is expected to provide
motivation for the university to license the technology to the private sector for
commercialization in expectation of royalty payments.
The Bayh-Dole Act has been seen as particularly successful in meeting its
objectives.  However, while the legislation provides a general framework to promote
expanded utilization of the results of federally funded research and development,
questions are being raised as to the adequacy of current arrangements.  Most agree
that closer cooperation among industry, government, and academia can augment
funding sources (both in the private and public sectors), increase technology transfer,
stimulate more innovation (beyond invention), lead to new products and processes,
and expand markets.  However, others point out that collaboration may provide an
increased opportunity for conflict of interest, redirection of research, less openness
in sharing of scientific discovery, and a greater emphasis on applied rather than basic
research.  Additional concerns have been expressed, particularly in relation to the
pharmaceutical and biotechnology industries, that the government and the public are
not receiving benefits commensurate with the federal contribution to the initial
research and development.
Actual experience and cited studies point to the conclusion that companies
which do not control the results of their investments – either through ownership of
patent title, exclusive license, or pricing decisions – tend to be less likely to engage
in related R&D.  The importance of control over intellectual property is reinforced
by the positive effect P.L. 96-517 has had on the emergence of new technologies and
techniques generated by U.S. companies.
This report will be updated as events warrant.
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The Bayh-Dole Act: Selected Issues in
Patent Policy and the Commercialization of
Technology
Introduction
Congressional interest in facilitating U.S. technological innovation led to the
passage of P.L. 96-517, Amendments to the Patent and Trademark Act, commonly
referred to as the “Bayh-Dole Act” after its two main sponsors former Senators
Robert Dole and Birch Bayh.  Under this 1980 law, as amened, title to inventions
made with government support is provided to the contractor if that contractor is a
small business, a university, or other non-profit institution.  The legislation is
intended to use patent ownership as an incentive for private sector development and
commercialization of federally funded research and development (R&D).  As a
response to congressional efforts to create a unified government patent policy
pertaining to inventions made with federal support, the Bayh-Dole Act promotes
cooperative activities among academia, small business, and industry leading to new
products and processes for the marketplace.
This paper discusses the rationale behind the passage of P.L. 96-517, its
provisions, and implementation of the law.  Observers generally agree that the Bayh-
Dole Act has successfully met its objectives.  However, some experts argue that the
issues associated with the law’s patent policies should be revisited given the current
R&D environment.  Much of the renewed interest is a result of the legislation’s effect
on the biotechnology and pharmaceutical industries where critics assert that the
private sector is receiving benefits to the detriment of the public interest.  Other
analysts, particularly in the defense arena, maintain that the existing rights
maintained by the government are too restrictive and prevent industry from meeting
national needs.  Many of these issues and concerns are similar, if not identical to
those addressed during the 15 to 20 years of deliberation prior to enactment of the
law.  These too will be explored to provide a context for current discussions.
An Historical Perspective
The Rationale
In the late 1970s, the United States Congress was involved in a series of
legislative debates over ways to promote private sector development and utilization
of federally funded research and development.  This was soon followed by expanded
congressional interest in additional means to foster technological advancement and
commercialization in industry.  During the 1980s and 1990s, various initiatives
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resulted in laws designed to encourage increased innovation-related activities in the
business community and to remove barriers to technology development, thereby
permitting market forces to operate.1 Laws promoting cooperative R&D and/or joint
ventures involving the federal government, industry, and academia have been a
cornerstone of the majority of these efforts and include legislation that created a
system to transfer technology from federal laboratories to the private sector;
implemented tax incentives for collaborative work; instituted direct and indirect
government support for increased R&D; and changed government patent policy to
provide an economic inducement for commercialization of federally funded
technology, the subject of this report.
P.L. 96-517, the Bayh-Dole Act, was one of the first of these initiatives.  Prior
to 1980, only 5% of government owned patents were ever used in the private sector
although a portion of the intellectual property portfolio had potential for further
development, application, and marketing.  The Bayh-Dole Act was developed, in
part, to address the low utilization rate of these federal patents.  The House report to
accompany H.R. 6933 (the House counterpart to the Senate bill that eventually
became the Bayh-Dole Act) noted that, at the time the bill was considered, 26
different agency policies existed regarding the use of the results of federally funded
R&D.  Generally the government retained title to inventions made with government
support whether the research was performed in federal laboratories, in universities,
or by individual companies.  Licenses to use the government patents were then
negotiated with firms either on a non-exclusive basis (meaning additional companies
could use the technology) or, more rarely, for the exclusive use by one manufacturer.
However, it was widely argued that without title (or at least an exclusive license) to
an invention and the protection it conveys, a company would not invest the
additional, and substantial time and money necessary to commercialize a product or
process for the marketplace.
In 1980, the federal expenditures for research and development totaled $55.5
billion (in constant 2000 dollars).2  The money typically was used to support research
and development to meet the mission requirements of the federal departments and
agencies (e.g., defense, public health, environmental quality) or to finance work in
areas where there was an identified need for research, primarily basic research, not
being performed in the private sector.  While the government’s investment led to
many new inventions that have profoundly influenced our society, many in Congress
were of the opinion that additional applications could be pursued by the private sector
if provided the proper incentives.
The intent of the new law was to replace this situation with a “single, uniform
national policy designed to cut down on bureaucracy and encourage private industry
to utilize government financed inventions through the commitment of the risk capital
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necessary to develop such inventions to the point of commercial application.”3
Expanded technology commercialization was to be accomplished by employing the
patent system to augment collaboration between universities (as well as other
nonprofit institutions) and the business community to ensure that inventions are
brought to market.  The Bayh-Dole Act also provides for the increased participation
of small firms in the national R&D enterprise under the assumption that these
companies tend to be more innovative than larger companies.
The Patent System: A Brief Overview
The patent system was created to promote invention and innovation.  Article I,
Section 8, Clause 8 of the U.S. Constitution states:  “The Congress Shall Have Power
... To promote the Progress of Science and useful Arts, by securing for limited Times
to Authors and Inventors the exclusive Right to their respective Writings and
Discoveries ...”  Patents are widely believed to encourage innovation by
simultaneously protecting the inventor and fostering competition.  They provide the
inventor with a right to exclude others, temporarily, from use of the invention
without compensation.  Patents give the owner an exclusive right for 20 years (from
date of filing) to further develop the idea, commercialize a product or process, and
potentially realize a return on the initial investment.  Concurrently, the process of
obtaining a patent places the concept in the public arena.  As a disclosure system, the
patent can, and often does, stimulate other firms or individuals to invent “around”
existing patents to provide for parallel technical developments or meet similar market
needs.4
Not everyone agrees that the patent system facilitates innovation.  Critics argue
that patents provide a monopoly which induces additional social costs and that cross
licensing between companies can result in exploitation of markets.  Some analysts
claim that the patent system was designed to assist the individual inventor and the
shift toward more R&D being performed in large companies has diminished the
patent’s value to society since these firms can utilize other methods to protect their
investments including lead time and trade secrets.
The importance of patents varies among industrial sectors.  Patents are
perceived as critical in the drug and chemical industries in part because of the ease
of replicating the finished product.  While it is expensive, complicated, and time
consuming to duplicate an airplane, it is relatively simple to chemically analyze a pill
and reproduce it.5 The degree to which industry perceives patents as effective has
been characterized as “positively correlated with the increase in duplication costs and
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time associated with patents.”6  In certain industries, patents significantly raise the
costs incurred by nonpatent holders wishing to use the idea or invent around the
patent — an estimated 40% in the pharmaceutical sector, 30% for major new
chemical products, and 25% for typical chemical goods — and are thus viewed as
significant.  However, in other industries, patents have much smaller impact on the
costs associated with imitation (e.g. in the 7%-15% range for electronics), and may
be considered less successful in protecting resource investments.7
Patents provide an economic incentive for companies to pursue further
development and commercialization.  Studies have shown that research funding
accounts for approximately one-quarter of the costs associated with bringing a new
product to market.  According to The Economist, “A dollar’s worth of academic
invention or discover requires upwards of $10,000 of private capital to bring [it] to
market.”8  Patent ownership is seen as a way to encourage the additional, and often
substantial investment necessary for new goods and services, particularly in the case
of small business.  In an academic setting, the possession of title to inventions is
expected to provide motivation for the university to license the technology to the
private sector for commercialization in anticipation of royalty payments.
University-Industry Cooperation
Changes to the patent laws embodied in the Bayh-Dole Act had as an objective
the facilitation of collaborative ventures between and among academia, industry, and
government.  In 1980, universities performed 14% of the R&D undertaken in the
United States (similar to today); much of this fundamental research basic to
technological advance.9  The work is accomplished as part of the education process
and provides training for scientists, engineers, and managers subsequently employed
by the private sector.
Universities, however, generally do not have the means of production necessary
to take the results of research and generate marketable products. Such activities are
carried out by industry.  Thus, the emphasis in the Bayh-Dole Act on the promotion
of cooperative efforts between academia and the business community.  By providing
universities with intellectual property ownership with which to pursue and structure
collaborative ventures, the legislation encourages the two sectors to work together
to generate new goods, processes, and services for the marketplace.  Such joint work
allows for shared costs, shared risks, shared facilities, and shared expertise. 
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Prior to World War II, industry was the primary source of funding for basic
research in universities.  This financial support helped shape priorities and build
relationships.  However, after the war, the federal government supplanted the private
sector as the major financial contributor and became the principal determinant of the
type and direction of the research performed in academic institutions.  This situation
oftentimes resulted in a disconnect between the university and industrial
communities.  Because the private sector and not the government typically is
involved in commercialization, the difficulties in moving an idea from the research
stage to a marketable product or process appeared to have been compounded.  Thus,
efforts to encourage increased collaboration between and among the sectors through
the Bayh-Dole Act were expected to augment the contribution of both parties to
technological advancement.
Small Business 
Special consideration concerning patent title is given to small businesses in part
because of the role these companies were seen as playing in the generation of new
jobs and in technological advancement.  Research supported by several federal
agencies concluded that small, high technology companies are the source of
significant innovation.  An often cited 1982 study financed by the Small Business
Administration determined that small firms were 2.4 times as innovative per
employees as large companies.10  Similar work performed at the time the legislation
was being considered found that firms of less than 1,000 employees were responsible
for more major innovations than large firms in the years 1953-1966 and for an equal
number from 1967-1973.11  A study of national and regional data by the Federal
Reserve Bank of Chicago concluded that “small firms – those with 20 or fewer
employees –  create a larger proportion of new jobs than their share of employment
in the economy and continue to create jobs even during recession.”12
However, certain caveats need to be stated particularly within the context of
small business, innovation, and technology development.  Over the years, experts
have argued that the contribution of small firms to the economy is overstated.  Marc
Levinson, writing in Dun’s Business Month, maintained that small companies tended
to produce fewer goods than larger ones because they are less capital intensive and,
on the whole, add less to the gross national product because they offer lower salaries
and often do not provide health insurance or pension plans.13  Professors Zoltan Acs
(University of Baltimore) and David Audretsch (University of Indiana) argued that
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the relationship between company size and innovation capacity varies by industry.14
Others maintain that there is no conclusive evidence that firm size affects the
“success” of R&D.15
An important factor affecting the ability of small companies to effect
technological advance is the relationship between these firms and large corporations,
a concept that is reflected in the provisions of the Bayh-Dole Act.  It appears evident
that “small high-tech companies play a critical and diverse role in creating new
products and services, in developing new industries, and in driving technological
change and growth in the U.S. economy,” as a National Academy of Engineering
study concluded.16  The reasons for this include the ability of these firms to rapidly
develop markets, generate new goods and services and offer product diversity.  Small
businesses tend to be willing to take those technological risks that are not taken by
large firms and may be in a position to quickly exploit market opportunities.17  Yet,
while small businesses can serve as the source of new products and processes, they
often “cannot take advantage of their initial technological lead to establish a secure
foothold in the key markets.”18 
Bayh-Dole and Related Law
Provisions
In enacting P.L. 96-517, the Congress accepted the proposition that vesting title
to the contractor will encourage commercialization and that this should be used to
support innovation in certain identified sectors.  The law states: 
It is the policy and objective of the Congress to use the patent system to promote
the utilization of inventions arising from federally-supported research or
development; ... to promote collaboration between commercial concerns and
nonprofit organizations, including universities; ... to promote the
commercialization and public availability of inventions made in the United States
by United States industry and labor; [and] to ensure that the Government obtains
sufficient rights in federally-supported inventions to meet the needs of the
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Government and protect the public against nonuse or unreasonable use of
inventions....19
Each nonprofit organization (including universities) or small business is
permitted to elect (within a reasonable time) to retain title to any “subject invention”
made under federally funded R&D; except under “exceptional circumstances when
it is determined by the agency that restriction or elimination of the right to retain title
to any subject invention will better promote the policy and objectives of this
chapter.”20 The institution must commit to commercialization within a
predetermined, agreed upon, time frame.  As stated in the House report to accompany
the bill, “the legislation establishes a presumption [emphasis added] that ownership
of all patent rights in government funded research will vest in any contractor who is
a nonprofit research institution or a small business.”21
Certain rights are reserved for the government to protect the public’s interests.
The government retains “a nonexclusive, nontransferable, irrevocable, paid-up
license to practice or have practiced for or on behalf of the United States any subject
invention throughout the world....”  The government also retains “march-in rights”
which enable the federal agency to require the contractor (whether he owns the title
or has an exclusive license) to “grant a nonexclusive, partially exclusive, or exclusive
license in any field of use to a responsible applicant or applicants....” (with due
compensation) or to grant a license itself under certain circumstances.  The special
situation necessary to trigger march-in rights involves a determination that the
contractor has not made efforts to commercialize within an agreed upon time frame
or that the “action is necessary to alleviate health or safety needs which are not
reasonably satisfied by the contractor....”22
The government is “authorized” to withhold public disclosure of information
for a “reasonable time” until a patent application can be made.  Licensing by any
contractor retaining title under this act is restricted to companies which will
manufacture substantially within the United States.  Initially, universities were
limited in the time they could grant exclusive licenses for patents derived from
government sponsored R&D to large companies (5 of the then 17 years of the patent).
This restriction, however, was voided by P.L. 98-620, the Trademark Clarification
Act of 1984.  According to S.Rept. 98-662, extending the time frame for licensing
to large firms “is particularly important with technologies such as pharmaceuticals,
where long development times and major investments are usually required prior to
commercialization.”23
Most experts continue to argue that patent exclusivity is important for both large
and small firms.  In a February 1983 memorandum concerning the vesting of title to
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inventions made under federal funding, then President Ronald Reagan ordered all
agencies to treat, as allowable by law, all contractors regardless of size the same as
prescribed in P.L. 96-517.  This, however, does not have a legislative basis.  P.L. 98-
620, noted above, further amended Bayh-Dole by loosening the time limitations for
both disclosure of an invention to the government agency and for the amount of time
provided within which to elect to take title.  Nonprofit institutions were subsequently
permitted to assign title rights to another organization (e.g., one which markets
technology) and government-owned, contractor-operated laboratories (primarily
those of the Department of Energy) run by nonprofits were permitted to retain title
to inventions made in the facility with the exception of those dedicated to naval
nuclear propulsion or weapons development.  In addition, the Federal Technology
Transfer Act (P.L. 99-502) allows firms regardless of size to be awarded patents
generated under a cooperative research and development agreement (CRADA) with
a federal laboratory.24
Implementation and Results
The Bayh-Dole Act appears to have met its expressed goals of using “the patent
system to promote the utilization of inventions arising from federally-supported
research or development; ... and to promote collaboration between commercial
concerns and nonprofit organizations, including universities....”25  In one of the
earliest studies of the legislation, the General Accounting Office (GAO) found
agreement among  university administrators and small business representatives that
P.L. 96-517 had “a significant impact on their research and innovation efforts.”26
While noting it was not correct to generalize about academia from the 25 universities
studied, GAO did find that by 1987 all  university administrators questioned
indicated that the Bayh-Dole Act had “been significant in stimulating business
sponsorship of university research, which has grown 74 percent ...” from FY1980 to
FY1985.27  According to the National Science Foundation (NSF), industry support
for academic research grew faster than any other funding source until FY2002.
Industry financing expanded from 3.9% of university R&D in 1980 to 7.2% in 2000,
although by FY2004 industry support had dropped to 4.9% of academic R&D due to
market conditions.  In 1980, federal financing comprised 67.5% of the total academic
undertaking; by 2000 federal support declined to 58.2% of university funding, yet
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increasing to 63.8% in FY2004.28  It should be noted, however, that the federal
government still remains the major source of academic research funding.
The majority of the university personnel involved in the GAO study indicated
that the increase in industry support for research at universities was “directly”
attributed to the patent changes in P.L. 96-517 and P.L. 98-620.  Academic faculty
interviews conducted by GAO found that “since businesses knew that universities
could take title to federally funded inventions, they no longer were concerned that
their research efforts could be ‘contaminated’ by federal funding with the possibility
that a federal agency could assert title rights to resulting inventions.”29 All
respondents agreed that the removal of licensing restrictions on nonprofit institutions
(including universities) by P.L. 98-620 was of vital importance in promoting
industry-university interaction.30  This was reinforced by the finding that 9 out of 10
business executives questioned identified the Bayh-Dole Act as an “important factor”
in their decisions to fund R&D in academia.31
Another GAO study published in May of 1998 reported that agency and
university representatives believed the Bayh-Dole Act was meeting its goals as
articulated by the Congress and the law had a positive impact on all involved.
Academia was “receiving greater benefits from their inventions and were transferring
technology better than the government did when it retained title to inventions.”32  In
addition, the report states that the increased commercialization of federally funded
research that resulted from the implementation of the act, positively affected both the
federal government and the American people.33
Other experts agree.  Yale President Richard Levin argues that the purpose of
the Bayh-Dole Act is to transition the results of government funded research “into
practice for the benefit of humanity ...” and that results indicate a “pretty emphatic
positive answer that the Bayh-Dole Act has created public benefits” with minimal
costs.34  As stated in a recent article in The Economist, the Bayh-Dole Act is
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“[p]robably the most inspired piece of legislation to be enacted in America over the
past half-century....”35
One of the major factors in the reported success of the Bayh-Dole Act is the
certainty it conveys concerning ownership of intellectual property.  The Director of
Stanford University’s Office of Technology Licensing, Katherine Ku, notes that
exclusivity is what motivates firms to invest financial and human resources in
technology development.36  It provides an incentive for universities to take the time
and effort to pursue a patent and to license those patents in its portfolio.  This has led
to a significant increase in academic patenting.  In 1980, 390 patents were awarded
to universities;37 by 2003, this number increased to 3,259.38 
Academia has become a major source of innovation for local and regional
economic development.  In the latest published survey (FY2004) performed by the
Association of University Technology Managers (AUTM), universities identified 567
new products that were marketed that year based on academic R&D.  In addition, the
survey indicated that during FY2004 more than 462 new companies had been created
to commercialize university research, small businesses are primarily  responsible for
the commercialization, and 74.5% of the new firms were located in the same state as
the university. Since 1980, more than 4,500 new companies have been created to
develop and market academic R&D.  Of these, 2,671 were still in operation by the
close of FY2004.39
The number of start-up companies created during FY2004 was 23.5% more than
the 374 created in FY2003.  Many of the start-up businesses were associated with just
seven schools including the Massachusetts Institute of Technology (MIT), the
University of California, California Tech, the University of Minnesota, the Johns
Hopkins University, the University of Utah, and the University of Virginia.40  Studies
of technology transfer activities at MIT and the University of Pennsylvania indicate
that each active exclusive license generates $1 million of additional R&D investment
each year.41  The Association of University Technology Managers also found that
$1.4 billion in royalties were generated in FY2004 from 11,414 licenses.
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However, several analysts argue that “Bayh-Dole was only one of a number of
important factors behind the rise of university patenting and licensing activity.”42  In
a study of the technology transfer and patenting activities of the University of
California, Stanford University, and Columbia University, Professor David Mowery
(University of California, Berkeley) and his colleagues concluded that increased
federal funding for basic biomedical research, expanded research in biotechnology,
specific court rulings, and government policies augmenting what can be patented all
contributed to the rise in academic intellectual property activities.  According to their
assessment, the Bayh-Dole Act had “little impact on the content of academic
research.”  The pursuit of patenting and licensing at universities has expanded
because of changes in biomedical and biotechnology R&D, not because of the act.43
Yet, others criticize this assessment and point out that the act had the most
significant impact on universities that were not actively engaged in patenting prior
to its passage.44  As a result of the Bayh-Dole Act, in part, “University patenting
increased particularly rapidly during the second half of the 1980s and early 1990s.”45
This growth in patenting has been concentrated in “middle-tier” schools, not just the
top research universities.46  The Mowery et.al. study focused solely on universities
that were previously involved in patenting and licensing and may not have fully
considered patent problems that existed before the legislation was implemented.
According to critics of the study, the analysts also failed to take into account changes
in the venture capital industry that promoted the development of start-up companies
to commercialize the results of university R&D.47
While the effects on the small business sector have not been as extensively
studied, the results appear similar.  All eight small business owners interviewed by
the General Accounting Office for its 1987 study indicated that the patent changes
had a significant beneficial effect on research, development, and innovation in their
firms.48 Perhaps most illustrative of the influence of the Bayh-Dole Act on small
business is the biotechnology industry.  According to Dr. Bernadine Healy, the
former Director of the National Institutes of Health (NIH), P.L. 96-517 is responsible
for the development and growth of the biotechnology sector.49  The biotechnology
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industry primarily is composed of small firms that are developing technologies and
techniques derived from R&D funded by NIH.  Many of these companies are
established by NIH alumni or university professors previously supported by NIH
grants.  In Senate testimony delivered on August 1, 2001, Dr. Marie Freire, then
Director of the Office of Technology Transfer at NIH, stated that “[i]t is widely
recognized that the Bayh-Dole Act and the Federal Technology Transfer Act continue
to contribute to the global leadership of the U.S. biomedical enterprise....”  An
industry that was in its infancy when the Bayh-Dole Act was passed, biotechnology
firms now generate annual sales of $33.3 billion (2004), and employ 187,500
people.50
 The value of the Bayh-Dole Act might be reflected in state efforts to promote
industry-university cooperation based on the contributions of these activities to local
economic growth.  As Mark Myers, retired Senior Vice-President of Xerox, told a
meeting of the National Academy of Sciences (NAS), “[t]he role of the research
university is growing ever important as an economic force in our economy....”51  By
2000, the National Governors Association reports 13 states had created programs to
fund university-industry partnerships.52  In a report for the Biotechnology Industry
Organization (BIO), analysts found that there are biotechnology related initiatives in
40 states, including many that involve cooperative efforts between academia and the
private sector. Between 2000 and 2004, 19 states have developed specific bioscience
strategic plans.  Twenty-six states have at least one seed or venture capital program
to invest in small firms undertaking work in bioscience.  State laws also have been
changed to allow universities to become equity partners in start up firms designed to
commercialize academic R&D.53
Current Issues and Concerns
While the Bayh-Dole Act provides a general framework to promote expanded
utilization of the results of federally funded research and development, questions
have been raised as to the adequacy of current arrangements.  Most experts agree that
closer cooperation among government, industry, and academia can augment funding
sources (both in the private and public sectors), increase technology transfer,
stimulate more innovation (beyond invention), lead to new products and processes,
and expand markets.  However, others point out that cooperation may provide an
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increased opportunity for conflict of interest, redirection of research, less openness
in sharing of scientific discovery, and a greater emphasis on applied rather than basic
research.
The successes of the Bayh-Dole Act and the visibility of the results of its
implementation have generated certain concerns, many of which are associated with
the role of the university in research, as well as biomedical and biotechnology R&D,
particularly as related to the availability and cost of pharmaceuticals.  Several of
these issues are discussed below.  However, it is important to place the Bayh-Dole
Act in context.  The law is one significant factor in expanded industry, university,
small business collaboration, but not the only one.  Therefore, it may be difficult to
assess what concerns are the direct result of the Bayh-Dole Act and which arise from
the overall research environment.  The rising costs associated with the performance
of research and development, the availability of venture capital, increased R&D
outsourcing by large firms, and expanded federal funding for biomedical research all
contribute to increased interaction among the parties.  Additional legislative
initiatives including the research and experimentation tax credit, the National
Cooperative Research Act, the small business technology transfer program, the
advanced technology program, and cooperative R&D agreements established by the
Stevenson-Wydler Technology Innovation Act all facilitate joint R&D activities
leading to the commercialization of new technologies for the marketplace.54 
Recoupment
Over the years, several legislators have suggested that the government  “recoup”
its investments from firms using federally supported research and development after
profits are generated.  This is particularly true in the area of pharmaceuticals.   Such
arguments are similar to those that were identified and considered as part of the
original legislative debate over patent policy and cooperative R&D.  Congress, over
20 or more years, weighed these issues and decided that, in the case of patent and
technology policies, the benefits to the Nation brought about by increased innovation
were paramount.  The passage of the Bayh-Dole Act represented a determination that,
with respect to certain types of organizations, the economic incentive to realize a
return on investment provided by a patent is necessary to stimulate companies to
provide the often substantial financial commitment to turn federally-funded R&D
into marketable technologies and techniques.   This decision was based on several
determinations deriving from the rationale for federal support of basic research, the
importance of technological progress to the Nation, and the critical role of private
sector commercialization in technological advancement.
Federal support for basic research is founded, in large part, on the understanding
that the rate of return to society as a whole generated by investments in research is
significantly larger than the benefits that can be captured by any one firm performing
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it.55  It has been estimated that the returns to society generated by investments in
basic research are approximately twice those to the company performing the work.
Government support reflects a consensus that basic research is the foundation for
many innovations, but that incentives for private sector financial commitments are
dampened by the fact that spending for R&D runs a high risk of failure.  Even results
of fruitful R&D often are exploited by other domestic and foreign companies, thus
resulting in underinvestment in research by the private sector.  The returns from basic
research are generally long term, sometimes not marketable, and not always evident.
It is now widely accepted that “from one-third to one-half of all [U.S.] growth
has come from technical progress, and that it is the principal driving force for long-
term economic growth and the increased standards of living of modern industrial
societies.”56  Technological advancement can clearly contribute to the resolution of
those national problems which are amenable to technological solutions.  Such
progress is achieved through innovation, the process by which industry provides new
and improved products, processes, and services.  An invention becomes an
innovation when it has been integrated into the economy such that the knowledge
created results in a new or improved good or service that can be sold in the
marketplace or is applied to production to increase productivity and quality.  It is only
through commercialization, a function of the business sector, that a significant
stimulus to economic growth occurs.  Thus, there is congressional interest in
accelerating development and commercialization activities in the private sector
through the Bayh-Dole Act as well as other legislation.
Actual experience and cited studies point to the conclusion that companies
which do not control the results of their investments – either through ownership of
patent title, exclusive license, or pricing decisions – tend to be less likely to engage
in related R&D.  This fact is reflected in the provisions of the Bayh-Dole Act (as well
as other laws).  Providing universities, nonprofit institutions, and small businesses
with title to patents arising from federally-funded R&D offers an incentive for
cooperative work and commercial application.  Royalties derived from intellectual
property rights provide the academic community an alternative way to support further
research and the business sector a means to obtain a return on their financial
contribution to the endeavor.  While the idea of recoupment was considered by the
Congress in hearings on the legislation, it was rejected as an unnecessary obstacle,
one which would be perceived as an additional burden to working with the
government.  It was thought to be particularly difficult to administer.  Instead,
Congress accepted as satisfactory the anticipated payback to the country through
increased revenues from taxes on profits, new jobs created, improved productivity,
and economic growth.  For example, according to the MIT Technology Licensing
Office, 15% of the sales of licensed products derived from federally funded
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university research is returned to the government in the form of income taxes, payroll
taxes, capital gains taxes, and corporate income taxes.  This is estimated to be 6 times
the royalties paid by companies to the universities.57  The emergence of the
biotechnology industry and the development of new therapeutics to improve health
care are other prominent indications of such benefits.  These benefits have been
considered more important than the initial cost of the technology to the government
or any potential unfair advantage.
Government Rights: Royalty Free Licenses and Reporting
Requirements
As discussed above, the government retains certain rights under the Bayh-Dole
Act to protect the public interest.  The act states that the government is provided a
“nonexclusive, nontransferable, irrevocable, paid-up license to practice or have
practiced for or on behalf of the United States any subject invention throughout the
world....”  This license, commonly known as a “royalty free license,” has been the
subject of some discussion including whether or not this permits government
purchasers to obtain discounts on products developed from federally funded R&D,
particularly pharmaceuticals.  A July 2003 GAO report addressed this issue and
concluded that the license entitles the government to practice or have practiced the
invention on the government’s behalf, but “does not give the federal government the
far broader right to purchase, ‘off the shelf’ and royalty free (i.e. at a discounted
price), products that happen to incorporate a federally funded invention when they
are not produced under the government’s license.”58  The study goes on to say that
rights in one patent do not “automatically” permit rights in subsequent, related
patents.59  Because the government apparently holds few licenses on the biomedical
products it purchases (generally through the Veteran’s Administration and the
Department of Defense),60 federal officials indicated that procurement costs were best
reduced by use of the Federal Supply Schedule and national contracts.61  Government
licenses are used primarily in the performance of research in the biomedical area.62
A related issue is that of tracking the government’s interest in patents resulting
from federally funded research and development.  In an August 1999 study, GAO
noted that federal contractors and grantees were not meeting the reporting
requirements associated with the Bayh-Dole Act, making it difficult to identify and
assess what licenses the government retained, among other things.63  Two years later,
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in a follow-up report, GAO stated that four of the five agencies had taken steps to
insure improved compliance with the law including several new monitoring systems,
although more needed to be done.64  Of particular interest is iEdison, created by the
NIH, which electronically tracks federal inventions and is used by other agencies in
addition to NIH.65
University Research
A question often posed is whether or not patent ownership rights provided by
P.L. 96-517 have interfered with the traditional operating procedures of academia.
A fear is that private sector funding of university R&D has led to conflicts of interest
by scientists performing the research, particularly when academics have equity
positions in the relevant companies.  There are concerns that industry agendas will
distort or supplant the basic research and educational responsibilities of academia.
Complaints have also been expressed that the free exchange of ideas and scientific
discovery are constrained as a result of both the university and the business
community’s interest in protecting their competitive positions.
The issue of conflict of interest is a complex one particularly when trying to
determine what direct role the Bayh-Dole Act has in generating such concerns and
what are the results of other factors that have lead to increased industrial funding of
university research.  As noted above, laws that provide tax incentives for private
sector financing of university basic research and facilitate technology transfer and
cooperative R&D among government, industry, and academia, as well as changes in
the way companies obtain the basic research necessary for product development
shape the environment within which academic research is pursued.  Thus, as argued
by Stanford University’s Katherine Ku, it is necessary to evaluate criticisms of the
Bayh-Dole Act and to understand that the success of the law has made many in
government uncomfortable despite the clear guidelines for technology transfer it
established.66
Senior Research Scholar Mildred Cho (Stanford University Center for
Biomedical Ethics) and her coauthors assert that the Bayh-Dole Act:
has created opportunities for conflict of interest for university faculty members
because academic-industry partnerships can offer direct financial rewards to
individual faculty members in the form of consulting fees, royalties, and equity
in companies while simultaneously funding these faculty members’ research.67
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This, it is argued, has resulted in situations where the researcher’s ties to private
sector interests may not be evident and may adversely affect “the quality, outcome,
and dissemination of research.”68  Other studies indicate that obligations to industry
“pose a threat to scientific integrity.”69  Private sector funded research tends to
generate conclusions favorable to industry; however, the factor that is primarily
associated with the withholding or delay of information is the involvement of the
scientist in bringing his research to market in a product, not the industrial financing
itself.70
Data collected by Harvard Medical School Professor David Blumenthal and his
colleagues also support the assessment that involvement in commercialization
activities is related to delays in publication.71  This study indicated that approximately
20% of life science researchers delayed publication of their studies more than six
months at least once for reasons associated with patents and commercialization
considerations.  Almost 9% of faculty refused to share research or materials with
other university scientists in the past three years.  However, the authors conclude that
“Withholding of research results is not a widespread phenomenon among life-science
researchers.”72  A survey of industry-university research centers by Wesley Cohen
(now at Duke University), et. al. found that over half of the centers permitted firms
to request publication delays and 35% of the institutions allowed researchers to delete
information prior to publication.  At those centers with a mission to improve
industrial products and processes, 63% allowed publication delays and 54%
permitted the deletion of information.73
Delays in publication and the free flow of information from academia, according
to Carnegie Mellon University Professor Richard Florida, “may well discourage or
even impede the advancement of knowledge, which retards the efficient pursuit of
scientific progress, in turn slowing innovation in industry.”74  Professor Florida also
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points to concerns over the increasing number of academic institutions taking equity
positions in and/or incubating spin-off companies.  These actions “simply tend to
distract the university from its core missions of conducting research and generating
talent.”  Professor Florida concludes that publication delays and greater secrecy in the
research process resulting from implementation of the Bayh-Dole Act have shifted
the university away from the pursuit of its traditional goals. 
Other experts, including Robert Barchi, Provost of the University of
Pennsylvania, maintain that the Bayh-Dole Act has not generated a significant set of
issues concerning conflicts of interest and publication delays primarily because of the
importance of academic freedom to the faculty.75  Publications are the basis for
promotion and tenure and methods to respect reasonable intellectual property
protection have been established.  Similarly, as noted by Professor Pam Samuelson
(University of California, Berkeley), conflicts of interest would jeopardize  tenure
thus regulations are in place to instruct faculty what is required of them.76 
In response to these issues, many universities have hired professional technology
managers to work with faculty and to address patents.  Universities with extensive
research capabilities and resources were the first to create offices of technology
transfer; after passage of the Bayh-Dole Act these offices were established with much
greater frequency.77 These university technology transfer offices have established
guidelines  to cover industry-university relationships, with education and publication
remaining academic priorities.78  The financial rewards derived from patenting are
only a small portion of the total amount of R&D funding for academic institutions
(3% in FY2000)79 and what substantial money does flow into individual institutions
tends to be the result of one “blockbuster” patent. University technology managers
report that the major reason for patent licensing is commercialization, not profit,
particularly since the cost of a patent, which can run approximately $10,000, is so
high.80  While the Bayh-Dole Act focused universities on “commercially relevant
technologies and closer ties between research and technological development,”81 the
CRS-19
82
 Lita Nelson, “Increase of Intellectual Property Licensing at Universities Stems from
Changes in Funding and Legislation,” MIT Tech Talk, Aug. 26, 1998 available at
[http://web.mit.edu].
83
 Available at [http://www.nih.gov].
84
 The Role of the University: Leveraging Talent, Not Technology.
85
 Eric Niller, “Biotech & Health: Report Fails to Address the Downside of Academic-
Industry Collaborations,” Wall Street Journal (Europe), Aug. 6, 2001, 17.
86
 Industry and the Academy: Uneasy Partners in the Cause of Technological Advance, 186.
87
 Jerry G. Thursby and Marie C. Thursby, University Licensing Under Bayh-Dole: What
are the Issues and Evidence?, May 2003. 
costs of patenting are such that “most university licensing offices barely break
even.”82
University limitations on outside research, expeditious publication obligations
mandated for certain federally-funded R&D, and conflict of interest provisions also
help to preserve a balance between federal policies like the Bayh-Dole Act that
promote industry-university cooperation and concerns over excessive control of the
research environment by the business community.  For example, NIH requires grant
recipients to publish the results of their government funded R&D.  This is augmented
by tax code regulations necessitating prompt dissemination of actual research results
in order for a university or research institution to retain its tax exempt status.  NIH
also has policies and guidelines promoting the availability of patents arising from
federal funding for use by other scientists for research purposes without acquisition
of a license.83  
Critics argue that the Bayh-Dole Act is distorting the traditional role of the
university to the detriment of future technological development. Professor Florida
maintains that because universities are seen as “engines” of growth, they focus on
applied rather than fundamental research.  This has lead to unrealistic national and
local policies and practices that encourage the commercialization of academic
research while ignoring the real value of universities as the “nation’s primary source
of knowledge creation and talent.”84  Mildred Cho also asserts that university
research is “skewed” toward marketable products and not basic research.85  Studies
by Washington University researchers Dianne Rahm and Robert P. Morgan et. al.
indicate the greater the faculty interaction with industry the more the applied
research.86 
Other experts disagree.  A study of 3,400 faculty at six major research
institutions by Professors Jerry Thursby (Emory University) and Marie Thursby
(Georgia Institute of Technology) found that “the basic/applied split in research did
not change over the period 1983-1999 even though licensing had increased by a
factor greater than 10.”87  Data collected by NSF appear to support this assessment.
According to NSF, in 1980, basic research comprised 66.6% of academic R&D
endeavors while applied research and development were 33.4% of the total.  In 2004,
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the percent of academic R&D expenditures devoted to basic research increased to
75.2% while applied research and development declined to 24.8% of the total.88 
Commentators claim that the Bayh-Dole Act encourages the type of research
that is attractive to faculty.  James Severson, President of the Cornell Research
Foundation, testified before the House Committee on the Judiciary that
Today, the protection and commercialization of academic research is one way for
universities to attract, retain, and reward talented faculty who wish to see the
results of their research programs benefit society.  A commitment to the
protection of research results is important for universities to develop closer ties
to companies, and to attract additional funds to support research programs.89
As noted by Terry Young, Assistant Vice Chancellor for Technology Transfer
atTexas A&M University, the act requires funds generated by licensing to be used for
future education and research necessary to “deliver ‘real world’ products to the
public.”90  Assessing the legislation, the Biotechnology Industries Association,
contends that “Without the Bayh-Dole Act, few licensing agreements would be
executed between private companies and federally supported research institutions,
and the enormous investment our government makes in medical research would be
wasted.”91
Biotechnology and Pharmaceuticals
Many of the current concerns about the Bayh-Dole Act primarily arise out of its
application to the biotechnology and pharmaceutical industries.  Congressional
interest in providing lower cost drugs, particularly to seniors, has focused attention
on the role the act has had on the development of new pharmaceuticals for the
marketplace.  Certain critics maintain that the price of many therapeutics derived
from federally funded R&D are excessive considering the government’s financial
contribution.92  Others argue that the Bayh-Dole Act does not significantly affect
pharmaceutical prices and point to a July 2001 study by NIH that found only four of
the 47 FDA approved drugs generating $500 million a year were developed in part
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with NIH funded technologies.93  Although the government generally does not
directly support pharmaceutical research aimed at product development,94 legislative
attempts have been made to require cost controls or recoupment on drugs generated,
in part, with federal funds.  This is in sharp contrast to congressional and executive
branch efforts, particularly in the defense arena, to make it easier for firms to acquire
and utilize intellectual property associated with federally financed R&D.95
Funding for university R&D in the life sciences, particularly medical and
biological sciences, comprises by far the largest portion of academic research
support.  In 2004, 51% of total R&D expenditures at academic institutions went to
finance the medical and biological sciences.96  When the Bayh-Dole Act was passed
in 1980, 40% of the research spending at universities was in these areas.97  Industry’s
share of biomedical R&D grew from approximately 32% in 1980 to 62% in 2000
while at the same time, the federal share declined.98  According to the National
Science Foundation, the federal portion of academic research funding in biological
sciences declined from approximately 74% in 1980 to 70% in 2004 although
government support for medical research increased from approximately 64% to 67%
during the same time period.99  The federal government continues to be the primary
source of funding for university R&D in these areas.
Overall support for biological and medical sciences has grown significantly
since the passage of the Bayh-Dole Act.  As measured in constant 2000 dollars, total
(federal and non-federal) spending for academic R&D in these areas has increased
from $4,618 million in 1980 to $19013 million in 2003.100   This expanded support
is important in light of findings by the late University of Pennsylvania Wharton
School of Business Professor Edwin Mansfield showing that academic research was
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particularly significant in the development of new products and processes in the
pharmaceutical and medical device industries.101  His research indicated that between
1986 and 1994, 31% of new innovations would not have been developed without
substantial delay in the “absence of academic research.”
Interest and activity in the biomedical and biotechnology sectors has sparked
some concern over the effects of the Bayh-Dole Act on research in these areas.
According to information provided by the Boston Consulting Group, in the years
between 1990 and 1999, new gene patents granted increased from about 400 to 2,800
while the number granted to universities expanded from 55% to 73% during that time
period.102  Similarly, the number of U.S. biotechnology patents granted each year
grew from 1,765 in 1990 to 7,763 in 2002.103  The focus on intellectual property has
led critics to charge that the Bayh-Dole Act encourages the patenting of fundamental
research which, in turn, prevents further biomedical innovation.   Law professors
Rebecca Eisenberg (University of Michigan) and Arti Rai (University of
Pennsylvania) argue that due to the legislation, “[p]roprietary claims have
increasingly moved upstream from the end products themselves to the ground-
breaking discoveries that made them possible in the first place.”104  While patents are
designed to spur innovation, Rai and Eisenberg maintain that certain patents hinder
the process.  From their perspective, by permitting universities to patent discoveries
made under federal funding, the Bayh-Dole Act “draws no distinction between
inventions that lead directly to commercial products and fundamental advances that
enable further scientific studies.”105  These basic innovations are generally known as
“research tools.”
Eisenberg and Richard Nelson of Columbia University argue that ownership of
research tools may “impose significant transaction costs” that result in delayed
innovation and possible future litigation.106  It also can stand in the way of research
by others:
Broad claims on early discoveries that are fundamental to emerging fields of
knowledge are particularly worrisome in light of the great value, demonstrated
time and again in history of science and technology, of having many independent
minds at work trying to advance a field.  Public science has flourished by
permitting scientists to challenge and build upon the work of rivals.107
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Similar concerns were expressed by Harold Varmus, President of Memorial Sloan-
Kettering and former Director of NIH.  In July 2000 prepared testimony, he spoke to
being “troubled by widespread tendencies to seek protection of intellectual property
increasingly early in the process that ultimately leads to products of obvious
commercial value, because such practices can have detrimental effects on science and
its delivery of health benefits.”108  While the Bayh-Dole Act and scientific advances
have helped generate a dynamic biotechnology industry, there have been changes that
“. . .are not always consistent with the best interests of science.”109
However, as Varmus and others acknowledge, the remedies to this situation are
not necessarily associated with the Bayh-Dole Act.  Yale President Richard Levin
notes that while some research should be kept in the public domain, including
research tools, the fact that it is privatized is not the result of the Bayh-Dole Act, but
rather the result of patent law made by the courts and the Congress.  Therefore, he
believes that changes to the act are not the appropriate means to address the issues.110
Current law, as reaffirmed by court decisions, permits the patenting of research
tools.  However, there have been efforts to encourage the widespread availability of
these tools.  Marie Freire testified that the value to society is greatest if the research
tools are easily available for use in research.  She asserted that there is a need to
balance commercial interests with public interests.111  To achieve this balance, the
NIH has developed guidelines for universities and companies receiving federal
funding that make clear research tools are to be made available to other scientists
under reasonable terms.112  In addition, the U.S. Patent and Trademark Office recently
made changes in the guidelines used to determine the patentability of biotechnology
discoveries.
A study by Professors John Walsh (University of Illinois, Chicago), Ashish
Arora (Carnegie Mellon University), and Wesley Cohen (Duke University) found that
although there are now more patents associated with biomedical research, and on
more fundamental work, there is little evidence that work has been curtailed due to
intellectual property issues associated with research tools.113  Scientists are able to
continue their research by “licensing, inventing around patents, going offshore, the
development and use of public databases and research tools, court challenges, and
simply using the technology without a license (i.e., infringement).”  According to the
authors of the report, private sector owners of patents permitted such infringement
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in academia (with the exception of those associated with diagnostic tests in clinical
trials) “partly because it can increase the value of the patented technology.”
Concluding Observations
 The discussion surrounding changes to the patent laws in 1980 and 1986, and
the debate over technology transfer since the late 1970s, acknowledged many of the
issues currently being explored.  As a result of expressed concerns, certain safeguards
were built into the activities authorized by the Bayh-Dole Act.  As discussed
previously, march-in rights, the government’s retention of an irrevocable license to
patents generated under federally funded R&D, publication requirements, and
commercialization schedules, among other things, all are incorporated into the
process to protect the public interest.  While there is a potential for creating an
“unfair” advantage for one company over another, this is balanced against the need
for new technologies and techniques and their contribution to the well-being of the
Nation.
Despite arguments that title should remain in the public sector where it is
accessible to all interested parties, the earlier lack of exclusivity interfered with the
further development and commercialization of federally funded R&D.  During the
1980s, Congress determined that the dispensation of patent rights to universities,
small businesses, and nonprofit institutions and cooperative efforts took precedence,
projecting the greater good generated by new products and processes that improve
the country’s health and welfare.  Lawmakers anticipated the economic benefits
through increased revenues from profits, wages, and salaries.  The government
receives a significant payback through taxes on profits and society benefits from new
jobs created and expanded productivity.  The importance of patent ownership has
been reinforced by the positive effects studies have demonstrated P.L. 96-517 is
reported to have had on the emergence of new technologies and new techniques
generated by American companies.
There remain areas of concern, as discussed above, that Congress may decide
to pursue.  Some argue, particularly with respect to pharmaceuticals and
biotechnology, that under the Bayh-Dole Act companies are receiving too many
benefits at the expense of the public.  Others, particularly in the defense arena, assert
that the existing rights retained by the government under the act are too restrictive
and are an impediment to meeting federal needs.  But the impact of the legislation is
still seen as significant.  As summed up by Howard Bremer, who was patent counsel
to the Wisconsin Alumni Research Foundation from 1960 through 1988:
One important factor, which is often overlooked, is that the success was achieved
without cost to the taxpayer. In other words, no separate appropriation of
government funds was needed to establish or manage the effort. In fact, it has
been estimated that the economic benefits flowing from the universities’
licensing activities adds about $41 billion to the United States economy.
Significant as that dollar amount is, it should not be overlooked that university
inventions, arising, as most of them do, from basic research, have led to many
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products which have or exhibit the capability of saving lives or of improving the
lives, safety and health of the citizens of the United States and around the world.
In that context their contribution to society is immeasurable.114
